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Background: Lateral epicondylitis of the elbow is a frequent condition with long-lasting symptoms. Corticosteroid
injection is increasingly discouraged and there is little knowledge on the combined effect of corticosteroid injection
and physiotherapy for acute conditions. We wanted to investigate the efficacy of physiotherapy alone and
combined with corticosteroid injection for acute lateral epicondylitis.
Methods: A randomized, controlled study with one-year follow-up was conducted in a general practice setting in
Sarpsborg, Norway. We included 177 men and women aged 18 to 70 with clinically diagnosed lateral epicondylitis
of recent onset (2 weeks to 3 months). They were randomly assigned to one of three treatments: physiotherapy
with two corticosteroid injections, physiotherapy with two placebo injections or wait-and-see (control). Physiotherapy
consisted of deep transverse friction massage, Mills manipulation, stretching, and eccentric exercises. We used double
blind injection of corticosteroid and single blind assessments. The main outcome measure was treatment success
defined as patients rating themselves completely recovered or much better on a six-point scale.
Results: One hundred fifty-seven patients (89 %) completed the trial. Placebo injection with physiotherapy showed
no significant difference compared to control or to corticosteroid injection with physiotherapy at any follow-up.
Corticosteroid injection with physiotherapy had a 10.6 times larger odds for success at six weeks (odds ratio 10.60,
p < 0.01) compared to control (NNT = 3, 99 % CI 1.5 to 4.2). At 12 weeks there was no significant difference between
these groups, but at 26 weeks the odds for success were 91 % lower (OR 0.09, p < 0.01) compared to control, showing
a large negative effect (NNT = 5, 99 % CI 2.1 to 67.4). At 52 weeks there was no significant difference. Both control and
placebo injection with physiotherapy showed a gradual increase in success.
Conclusions: Acute lateral epicondylitis is a self-limiting condition where 3/4 of patients recover within 52 weeks.
Physiotherapy with deep transverse friction massage, Mills manipulation, stretching, and eccentric exercises
showed no clear benefit, and corticosteroid injection gave no added effect. Corticosteroid injections combined
with physiotherapy might be considered for patients needing a quick improvement, but intermediate (12 to
26 weeks) worsening of symptoms makes the treatment difficult to recommend.
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Lateral epicondylitis of the elbow (tennis elbow) is fre-
quently encountered in general practice with an incidence
of 5.5 per 1000 person-years [1]. It is characterised by pain
and tenderness over the lateral humeral epicondyle and
pain on resisted dorsiflexion and radial deviation of the
wrist. It is usually a self-limiting condition, resolving in six
to 12 months regardless of treatment, but symptoms may
last up to two years or longer [2].
Most authors attribute the condition to a lesion in the
short radial extensor muscle [3, 4]. The aetiology of this
tendinopathy is probably degenerative rather than in-
flammatory [5, 6], and the term ‘lateral epicondylalgia’
has been proposed [7]. Patients with lateral epicondylitis
are usually treated in general practice, but there is no
consensus on which of many treatments is most effective.
Corticosteroid injections are increasingly discouraged be-
cause of recurrence despite showing a marked short-term
effect [8–10]. Physiotherapy with eccentric exercise and
specific manual therapy (‘Manipulation with Movement’)
show promising results [8, 10, 11]. The effect of combin-
ing physiotherapy with corticosteroid injection has been
investigated in three studies with different duration of
symptoms and length of follow-up [11–13]. None of these
studies showed any additional benefit of physiotherapy
compared with corticosteroid injection alone. Different
physiotherapeutic modalities were used in these studies.
We have found no randomised, controlled studies con-
ducted in general practice with long term follow-up that
have looked exclusively at acute conditions. We wanted
to investigate the effect of treatment on acute conditions.
Considering the aetiology of tendinopathies as a con-
tinuum from physiology to pathology [5, 14], there might
be less degeneration present in the tendon in acute stages
with less permanent change in collagen structure, which
might influence the effect of treatment. In general practice
patients may have less severe or shorter duration of symp-
toms than at outpatient clinics, possibly giving a different
study population and different effect of treatment.
For acute lateral epicondylitis in such a setting, we
wanted to investigate the short- and long-term effect of
physical treatment, which has been recommended [15].
We also wanted to see whether addition of corticosteroid
would show any benefit, and if the well-known initial posi-
tive effect of corticosteroid injection [16, 17] would be lon-
ger lasting when combined with physical treatment.
We used two treatment groups. One group received
corticosteroid injections and physical treatment, while
the other received placebo injections and physical treat-
ment. The placebo injections were assumed to have no
effect, but were included for blinding purposes. We also
included a control group receiving no treatment except
NSAIDs. The first two groups enabled us to compare the
treatment effect of corticosteroid injection to physicaltreatment alone. The control group enabled us to com-
pare the effect of corticosteroid injection with physical
treatment and physical treatment alone to a group repre-
senting the natural course of acute lateral epicondylitis.
We chose a treatment protocol comprising well-known
treatments based on earlier studies [8, 17], and our focus
was on commonly used treatments more than investigat-
ing specific treatment modalities. At the time of planning
the protocol (2008), there were no established standard
physical treatment, but eccentric training was included
based on promising results [8, 17, 18]. For practical and
pragmatic reasons, we chose not to include ultrasound or
other electrotherapeutic modalities.
Objectives
The objective of this study was to investigate the clinical
short- and long-term efficacy of corticosteroid injection
or placebo injection with a combination of physical
treatments for acute lateral epicondylitis in a primary
care setting compared with a control group only treated
with NSAIDs.
Methods
Trial design and setting
A randomized, placebo-controlled trial was conducted in
a primary care setting in the city of Sarpsborg, Norway,
as outlined in the published protocol [19]. The trial was
approved by The Regional Committees for Medical Re-
search Ethics - South East Norway, Faculty of Medicine,
University of Oslo, The Norwegian Social Science Data
Services and The Norwegian Medicines Agency, and all
patients gave written informed consent.
Participants
Patients aged 18–70 years seeing their general practi-
tioner with pain of recent onset from the lateral part of
the elbow were eligible for inclusion. Further inclusion
criteria were pain increase on resisted dorsiflexion of the
wrist with the elbow extended and the fingers flexed,
resisted radial deviation of the wrist, or resisted exten-
sion of the third finger.
We defined acute lateral epicondylitis as symptom
duration less than 3 months. To avoid light, self-limiting
conditions, we pragmatically chose to exclude patients
with less than 2 weeks symptom duration. We also ex-
cluded patients with tenderness within the muscle body
itself (Cyriax type IV) [20] to avoid misdiagnosis (e.g.,
nerve entrapment) and focus the treatment with manipu-
lation and injection on the tendon origin. Other exclusion
criteria were treatment with corticosteroid injection or
physiotherapy within the last 12 months, bilateral symp-
toms, previous surgical treatment for lateral epicondylitis,
deformities of the elbow, cervical radiculopathy, referred
pain from neck or shoulder, previous fractures or tendon
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previous allergic reactions or contraindications to corti-
costeroids, lidocaine, or NSAIDs, pregnancy or breast-
feeding, fertile females not on effective birth control,
and psycho-social or other reasons for not being able to
participate throughout the study.
Interventions
In a six week treatment period, patients received one of
three treatments: physiotherapy with two corticosteroid
injections and naproxen orally, physiotherapy with two
placebo injections and naproxen, or a wait-and-see treat-
ment with naproxen.
Physiotherapy
A cooperating physiotherapist treated patients twice
weekly for six weeks with deep transverse friction massage
at the tendon origin for 15 minutes, Mills manipulation
[21, 22] once each treatment session, and soft tissue treat-
ment with stretching of the radial wrist extensors. The pa-
tients received oral and written instructions for home
exercises daily for six weeks with eccentric exercise (three
times 30 repetitions) and isolated stretching of radial wrist
extensors (three times daily for 40 seconds). The eccentric
exercise was done within tolerable pain level during the
exercise by using a 500 ml bottle filled with increasing vol-
ume of water or sand as patients improved.
Corticosteroid injection
At start and after three weeks, patients received an injec-
tion with 10 mg triamcinolone acetonide (1 ml of 10 mg/
ml) or placebo (1 ml of 0.9 % isotonic saline) and 0.5 ml of
2 % lidocaine. With the patient in a supine position, the
elbow flexed, and the wrist pronated, the point of max-
imum tenderness was located. The needle was inserted at
90° down to the level of bone and then pulled back 1–
2 mm, leaving several small depots at the surface of the
tendon. The patient was informed of possible adverse ef-
fects and advised to avoid pain-provoking activities for the
rest of the day. The second injection was not given if there
had been adverse reactions or increase in symptoms.
General treatment and information
All groups received naproxen 500 mg twice daily for two
weeks for pragmatic reasons, since the control group
thus would receive some form of treatment in the initial
six-week period. Paracetamol could be taken at the pa-
tient’s own discretion up to 4 grams daily and its use
was recorded. No self-registration of medication was used.
General advice was given to all groups, including the nat-
ural course of the condition and expected duration of
symptoms. Patients were encouraged to use their arm as
usual, but avoid pain-provoking activities. Additional
treatment after the six-week treatment period and sickleave certification was given at the discretion of the gen-
eral practitioner.
Outcomes
A number of baseline characteristics were registered. The
primary outcome measures were the patients’ evaluations
of improvement after six, 12, 26, and 52 weeks [8]. On a
six point Likert scale (much worse-worse-a little worse-
some improvement-much improvement-completely re-
covered), a rating of much improvement or completely
recovered was defined as treatment success [8, 11].
Secondary outcome measures included elbow pain, af-
fected function and overall complaint, registered on a
100 mm Visual Analogue Scale (VAS). Pain-free and max-
imum grip strength was registered with a hand-held,
analogue dynamometer as a mean of three measurements
in a ratio of affected to unaffected side (Jamar Hydraulic
Hand Dynamometer-5030 J) [8, 23, 24]. Pain on resisted
dorsiflexion of the wrist and third finger was registered on
a three-point scale (none, some, definite) [16, 17] and pain
on eight every-day activities was registered using the Pain
Free Function Index [25, 26]. Patients were asked at each
follow-up after specific adverse events (increased pain in
elbow, heart burn, dyspepsia, reflux symptoms, abdominal
pain, gastritis, and ulcer) and checked for skin atrophy.
They were also asked about the need for additional treat-
ment and duration of sick leave.
Sample size
Sample size was based on the ability to detect a 25 %
difference in the success rate at three months. Earlier
studies have shown a large success rate of corticosteroid
injections for the first three months [8, 17]. Later, the
success rate increases regardless of intervention. Based
on earlier studies [17], we assumed a success rate of
55 % at three months in the least successful group. The
target sample size was estimated at 52 patients per
group (two tailed α: 0.05, β: 0.20) giving a total of 156
patients. With a loss to follow-up of 10 % and allocation
in three groups, we decided to include 180 patients.
Since the drop-out rate stayed near the 10 % prediction
(20 drop-outs, 11 %), we decided to stop the inclusion at
177 patients.
Randomisation and blinding
A computerised randomisation schedule was prepared
by an independent researcher (ML), using numeric block
randomisation with variable block size. Stratification of
patients was not done. The patients were first assessed
by one of two trial doctors. If inclusion criteriae were
met, the patient was enrolled in the study. Only then
was an independent research assistant contacted, who,
by consulting the previously prepared randomisation
schedule, allocated the patient to one of three treatments
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proceeded to do the baseline registrations and start the
allocated treatment. A research assistant prepared the
syringes used for the injection treatment and concealed
its content by an opaque adhesive patch, thus blinding
the content of the injection for both administering doctor
and patient. To ensure blinded assessment of treatment
effect, in the follow-up period from week six patients saw
the other trial doctor, who was blinded for treatment. Pa-
tients were cautioned at each assessment not to disclose
their treatment, and the success of blinding was assessed
at 52 weeks by the trial doctor guessing which treatment
the patient had received.
Statistical methods and analysis
The statistical analysis was performed blinded to treat-
ment group on an intention-to-treat basis using SPSS
version 21 and Stata version 13. The percentage of treat-
ment success was presented unadjusted, calculated based
on the number of patients included, assuming those lost
to follow-up had no success as outcome. Numbers needed
to treat (NNT) was calculated using this unadjusted differ-
ence in success between groups at each follow-up.
Since a number of variables may have influenced re-
sults, we adjusted for these by using a regression model,
with the resulting odds ratio giving an often different
but more correct picture of the effect of the interventions.
Our data consisted of both between-group observations
and longitudinal data with observations at five different
time points (baseline, six, 12, 26 and 52 weeks). Such
observations within a subject tend to be correlated, and
we therefore used the Generalized Estimating Equations
(GEE) model to account for possible correlation between
repeated measurements over time [27]. Continuous miss-
ing data was handled by assuming data was missing com-
pletely at random (MCAR) in the GEE models.
Univariate GEE logistic regression models were fitted
to our primary outcome (treatment success) to identify
significant covariates. The significant covariates at p < 0.05
were: to be in paid work, presumed cause of condition be-
ing overuse of the arm or hand in usual activities, pain
score, affected function score, overall complaints score,
and maximum grip strength ratio, all measured at base-
line. Only these covariates were used in our final models
to adjust for the effect of treatment over time on the
binary responses (success of treatment and pain-free ex-
tension of wrist and third finger). For the continuous re-
sponses (pain, affected function, and overall complaints
on VAS scales, grip strength ratios and Pain Free Func-
tion Index), we used a linear GEE regression model ad-
justed for the same covariates.
We performed statistical tests on treatment effective-
ness at several time points. To reduce problems of mul-
tiple testing, we used a significance level of 1 % in theGEE models and computed the 99 % confidence inter-
vals, as other authors have done [8, 11]. P-values are
given in the tables. Differences between groups regard-
ing adverse events, use of additional treatments, and sick
leave were analysed at one time-point only (week 52).
We used a Chi-square test for independence with a 5 %
significance level. A one-way between-groups analysis of
variance was conducted to compare differences in sick
leave duration.
Results
Recruitment and participant flow
Two hundred fifty-six patients were referred to the study
between April 2009 and June 2012. Of these, 79 were
excluded; 69 did not meet the inclusion criteria and 10
declined to participate. A total of 177 patients were in-
cluded in the study. The trial was completed in June 2013,
with 157 patients (89 %) completing the primary outcome
at 52 weeks follow-up. This met the minimum number re-
quired from the sample size calculations. Figure 1 summa-
rizes the patient flow. 117 patients were randomized to
treatment with physiotherapy. One patient in the placebo
injection with physiotherapy group withdrew from the
study before receiving any treatment. 103 (89 %) of the
remaining 116 patients concluded the treatment in ac-
cordance with the physiotherapy protocol as assessed by
the treating physiotherapist (having attended at least 8 of
12 sessions), 53 (91 %) in the placebo injection with
physiotherapy group and 50 (85 %) in the corticosteroid
injection (CI) with physiotherapy group. All patients in
the injection groups received two injections except one
patient in the placebo injection with physiotherapy group,
who received only one injection.
Baseline data
Before start, baseline characteristics were registered
(Table 1). The groups were similar in regards to gender,
age, duration and overall severity of symptoms, grip-
strength and other characteristics.
Outcomes and estimations
Primary outcome
Unadjusted event rates of treatment success, defined as
participants rating themselves much improved or com-
pletely recovered on a six-point scale, are shown in Fig. 2
and Table 2. The control group and placebo injection
with physiotherapy group showed a gradual and very simi-
lar pattern of improvement, while the CI with physiother-
apy group showed a marked improvement at six weeks,
but then a lower rate of success at 12 and 26 weeks. At
52 weeks, the rates were similar across all groups. To com-
pare groups statistically, estimated odds ratios for treat-
ment success from the GEE regression model adjusted for
significant covariates are given in Table 2. Placebo injection
Fig. 1 Study flow diagram showing recruitment, randomisation to treatment groups, and follow up rates
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pared to control on any of the follow-ups. CI with physio-
therapy had a 10.6 times larger odds for success at six
weeks (odds ratio 10.60, p < 0.01) compared to control,
suggesting a large initial treatment effect (NNT= 3, 99 %
CI 1.5 to 4.2). At 12 weeks there was no significant dif-
ference between these groups, but at 26 weeks the odds
for success were 91 % lower (OR 0.09, p < 0.01) comparedto control, showing a large negative effect (NNT = 5, 99 %
CI 2.1 to 67.4). At 52 weeks there was no significant differ-
ence. There was no significant difference between placebo
injection with physiotherapy and CI with physiotherapy at
any follow-up.
Looking at within group differences, there was a gradual
increase in success over time for the control group, and
the increased odds ratio for success was statistically
Table 1 Baseline characteristics. Baseline characteristics of participants according to treatment groups and total study population.
Values are numbers (percentages) unless otherwise stated
Control Placebo injection
with physiotherapy
Corticosteroid
injection with
physiotherapy
Total
(n = 60) (n = 58) (n = 59) (N = 177)
Age years, mean (SD) 44.0 (9.7) 48.8 (9.4) 47.9 (9.6) 46.9 (9.7)
Women 25 (42) 20 (35) 26 (44) 71 (40)
Higher education* 15 (25) 24 (41) 13 (22) 52 (29)
Exercises regularly 30 (50) 32 (55) 24 (41) 86 (49)
Paid work 53 (88) 49 (85) 52 (88) 154 (87)
Paid work 53 (88) 49 (85) 52 (88) 154 (87)
Manual labor 36 (60) 29 (50) 35 (59) 100 (57)
On paid sick-leave now** 14 (26) 14 (29) 23 (44) 51 (33)
Duration of complaints (weeks, median (IQR)) 7.5 (4‐10) 8 (4‐10) 6 (4‐10) 8 (4‐10)
Dominant elbow affected 41 (68) 42 (72) 43 (73) 126 (71)
Pain every day past week 58 (97) 55 (95) 57 (97) 170 (96)
Use of analgesics past week 15 (25) 15 (26) 25 (42) 55 (31)
Acute start of symptoms 42 (70) 25 (43) 27 (46) 94 (53)
Similar complaints earlier ++ 16 (27) 9 (16) 16 (27) 41 (23)
Presumed cause
overuse, usual activitities 34 (57) 38 (66) 38 (64) 110 (62)
overuse, unusual activities 25 (42) 19 (33) 21 (36) 65 (37)
Patient’s preference for treatment
Physiotherapy 17 (28) 26 (45) 24 (41) 67 (38)
Injections 15 (25) 6 (10) 19 (32) 40 (23)
Wait and see 6 (10) 3 (5) 2 (3) 11 (6)
No preference 22 (37) 22 (38) 14 (24) 58 (33)
Pain Score on VAS (0‐100 mm) mean (sd) 48 (21.5) 53 (19.3) 56 (19.7) 52 (20.4)
Affected Function on VAS (0: not affected, 100:
very much affected)
mean (sd) 53 (21.8) 54 (22.5) 53 (21.7) 53 (21.9)
Overall Complaints on VAS (0: no complaints,
100: very large complaints)
mean (sd) 62 (20.5) 62 (19.3) 69 (17.1) 64 (19.2)
Pain-free grip strength ratio*** mean (sd) 35 (27) 38 (27) 37 (27) 36 (27)
Maximum grip strength ratio*** mean (sd) 72 (29) 77 (42) 70 (28) 73 (34)
Pain Free Function Index**** mean (sd) 5.4 (1.6) 5.3 (1.8) 5.5 (1.7) 5.4 (1.7)
Pain-free isometric dorsiflexion of wrist+ 0/60 (0) 0/58 (0) 2/59 (3) 2/177 (3)
Pain-free isometric extension of third finger+ 8/59 (14) 2/58 (3) 4/59 (7) 14/176 (8)
*: university/college
**: percentage of those with paid work
***: ratio affected/unaffected arm (x 100)
****: 0: full function, 8: no function
+: score 1 on 3 point Likert scale (1-no pain, 2-some pain, 3‐strong pain)
++: at least 3 months prior to current episode
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(Table 2). Placebo injection with physiotherapy also
showed a gradual increase in success rate. For CI with
physiotherapy, the percentage of success was high at six
weeks, but then lower at 12 and 26 weeks.Secondary outcomes
The GEE regression model showed overall no significant
differences in favour of either placebo injection with
physiotherapy or CI with physiotherapy compared to
control for most of the secondary outcomes (Table 3).
Fig. 2 Unadjusted percentage of success at each follow up, defined as participants rating themselves much improved or completely recovered
on a six-point scale
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mated odds for pain-free isometric wrist extension that
were 9.2 times higher for CI with physiotherapy compared
to placebo injection with physiotherapy at six weeks (OR
9.2, p < 0.01). At 52 weeks, the result was reversed, with
94 % lower odds of pain-free wrist extension (OR 0.06, p <
0.01). Another exception at 26 weeks was isometric exten-
sion of the third finger, where CI with physiotherapy had
83 % lower odds of pain-free extension compared to con-
trol (OR 0.17, p < 0.01) and 84 % lower odds compared to
placebo injection with physiotherapy (OR 0.16, p < 0.01).
No other statistically significant differences were found be-
tween the treatment groups.
For both control and placebo injection with physiother-
apy, there seemed to be a gradual within-group improve-
ment over time across all secondary outcomes (Table 3).
For CI with physiotherapy, there was a worsening across
most outcomes at 12 and 26 weeks.Sick leave and use of additional treatments
Twenty-three of patients in the control group used add-
itional treatment and 52 % had been on paid sick leave,
with a mean of 43 full days and 60 partial days on leave.
Similar values were found for the two treatment groups,
indicating that the condition considerably affects the func-
tion and activity of patients. There was no significant asso-
ciation between treatment and the use of paid sick leave
during the follow-up (p = 0.88, Table 4). For those on paid-
sick leave, a one-way analysis of variance showed nostatistically significant differences in mean duration of
sick leave for neither full (p = 0.25) nor partial (p = 0.07)
sick-leave. There was no significant association between
treatment and the number of patients receiving add-
itional treatments in each group (p = 0.63). When we
looked at each additional treatment, we found an associ-
ation between treatment group and use of additional
physiotherapy (p = 0.02). A post-hoc 2 × 2 comparison
showed significantly more use of additional physiother-
apy in the CI with physiotherapy group compared to the
placebo injection with physiotherapy group (p < 0.01)
(Table 4).
The assessors correctly guessed treatment allocation in
47 % of the total cases. For CI with physiotherapy, cor-
rect treatment was guessed in 61 % of cases, for placebo
injection with physiotherapy in 37 %, and for control in
44 % of cases. A Chi-square test for independence indi-
cated significant association between treatment group
and correctly guessing the treatment (p = 0.04). A post-
hoc 2 × 2 comparison showed significant differences be-
tween CI with physiotherapy and placebo injection with
physiotherapy (p = 0.01).Harms
There was no significant association between treatment
group and the number of reported adverse events (p = 0.51)
(Table 4). There were no serious adverse events. The most
frequently reported was mild gastrointestinal side effects,
which 15 % in the control group reported.
Table 2 Treatment success. Unadjusted event rates of treatment success, defined as participants rating themselves much improved
or completely recovered on a six point scale; estimated odds ratio for success between groups using logistic generalized estimating
equations (GEE) regression model adjusted for significant covariates with numbers needed to treat (NNT); estimated odds ratio for
success within each group compared to week 6 using logistic GEE regression model adjusted for significant covariates; 99 %
confidence intervals. NNT calculated from unadjusted treatment success values
Unadjusted percentage of treatment success (99 % CI) at each follow up
Control Placebo injection
with physiotherapy
Corticosteroid
injection (CI) with
physiotherapy
Follow up (n = 60) (n = 58) (n = 59)
weeks % (99 % CI) % (99 % CI) % (99 % CI)
6 15 (3 to27) 24 (10 to 39) 59 (43–76)
12 48 (32 to 65) 45 (28 to 62) 42 (26 to 59)
26 67 (51 to 82) 69 (53 to 85) 42 (26 to 59)
52 78 (65 to 92) 78 (64 to 92) 75 (60 to 89)
Estimated Odds Ratio (99 % CI) and NNT + for treatment success between groups
Placebo injection with
physiotherapy versus
control
P NNT
(99 % CI)
CI with physiotherapy
versus control
P NNT
(99 % CI)
CI with physiotherapy
versus placebo injection
with physiotherapy
P NNT (99 % CI)
OR > 1 favours first treatment in comparison
6 3.37 (0.72 to 15.82) 0.04 11 ** 10.60 (2.20 to 51.24)* <0.01 3 (1.5 to 4.2) 3.14 (0.72 to 13.75) 0.045 3 (1.8 to 7.5)
12 0.18 (0.02 to 1.47) 0.04 29 ** 0.15 (0.02 to 1.24) 0.02 17** 0.81 (0.10 to 6.37) 0.80 41 **
26 0.37 (0.04 to 3.35) 0.25 44 ** 0.09 (0.01 to 0.76)* <0.01 5 (2.1 to 67.4) 0.24 (0.03 to 2.05) 0.09 4 (2.0 to 26.3)
52 0.12 (0.01 to 1.50) 0.03 134 ** 0.17 (0.01 to 2.63) 0.10 27 ** 1.49 (0.13 to 17.12) 0.67 34 **
Estimated Odds Ratio (99 % CI) for treatment success compared to week 6 within each group
Control P Placebo injection
with physiotherapy
P CI with physiotherapy P
OR > 1 indicates improvement compared to week 6
12 7.17 (1.53 to 33.66)* <0.01 1.30 (0.32 to 5.26) 0.63 1.05 (0.23 to 4.75) 0.93
26 6.09 (1.27 to 29.29)* <0.01 2.25 (0.47 to 10.81) 0.18 0.55 (0.13 to 2.39) 0.29
52 14.84 (1.92 to 114.57)* <0.01 1.70 (0.34 to 8.43) 0.39 2.54 (0.40 to 16.01) 0.19
*: p < 0.01
**: the 99 % confidence interval for the absolute risk reduction extends from a negative number to a positive number, and a 99 % CI for the NNT cannot
be computed
+: NNT calculated from unadjusted treatment success values
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There were no significant differences between placebo
injection with physiotherapy and control for any out-
come at any follow-up. CI with physiotherapy showed
significantly higher odds for success compared to the
control group at six weeks, but at week 26 the effect was
negative. At 52 weeks there was no significant difference.
There was no statistical difference in odds ratio for suc-
cess between placebo injection with physiotherapy and
CI with physiotherapy at any follow-up. CI with physio-
therapy showed higher odds for pain-free wrist extension
compared to placebo injection with physiotherapy at six
weeks, but at 52 weeks the effect was negative. For ex-
tension of the third finger, CI with physiotherapy had
lower odds of pain-free extension than both control and
placebo injection with physiotherapy at 26 weeks.The absence of significant differences between CI with
physiotherapy and placebo injection with physiotherapy
show that there was no added effect of steroid injection
to physiotherapy, and the pattern of effect seemed to
follow the well-known trajectory of steroid injections. The
negative effect of CI with physiotherapy on self-rated suc-
cess at intermediate follow-up might be explained by the
fact that patients rated themselves worse compared to the
very good initial response. However, other outcomes did
indicate that there also was an objective worsening at
intermediate follow-up. The initially good response might
also have led patients to return to normal activity too
soon, and thus induce a recurrence of symptoms. The use
of corticosteroid might have delayed the tendon repair
process and thereby caused a worsening in the inter-
mediate term follow-up. The steroid injections were
Table 3 Secondary outcomes. Mean (sd) scores and percentage (99 % CI) for secondary outcome measures at each follow up. Between group differences in estimated mean
score using linear generalized estimating equations (GEE) regression model adjusted for significant covariates; between groups estimated odds ratio (OR) for no pain on two
isometric movements using logistic GEE regression model adjusted for significant covariates; 99 % confidence intervals
Mean scores (sd) for each intervention Difference in estimated mean score (99 % CI) between groups
Outcome
measure
Follow up Control Placebo
injection with
physiotherapy
Corticosteroid
injection (CI)
with physiotherapy
Placebo injection
with physiotherapy
versus control
P CI with physiotherapy
versus control
P CI with physiotherapy
versus placebo injection
with physiotherapy
P
Negative value favours first treatment in comparison
Pain Score on VAS (0: no pain, 100: worst pain)
6 weeks 44 (25) 45 (23) 29 (25) −3.7 (−12.4 to 5.0) 0.27 −3.2 (−12.0 to 5.6) 0.35 0.53 (−8.4 to 9.4) 0.88
12 weeks 33 (26) 33 (26) 41 (26) −3.7 (−12.5 to 5.1) 0.28 0.2 (−8.5 to 8.9) 0.95 3.9 (−4.9 to 12.7) 0.25
26 weeks 19 (22) 21 (22) 38 (28) −3.6 (−12.4 to 5.2) 0.29 1.8 (−7.0 to 10.6) 0.60 5.4 (−3.6 to 14.4) 0.12
52 weeks 13 (19) 9 (11) 19 (23) −6.0 (−14.9 to 2.9) 0.09 −2.9 (−11.8 to 6.0) 0.40 3.0 (−6.0 to 12.0) 0.38
Affected Function on VAS (0: not affected, 100: very much affected)
6 weeks 38(26) 45 (24) 25 (23) 8.3 (−1.8 to 18.4) 0.04 7.5 (−2.8 to 17.8) 0.06 −0.8 (−11.2 to 9.6) 0.85
12 weeks 34 (28) 32 (25) 37 (29) −1.2 (−11.5 to 9.0) 0.76 3.4 (−6.8 to 13.5) 0.40 4.6 (−5.7 to 14.9) 0.25
26 weeks 16 (20) 17 (22) 28 (25) 0.29 (−10.0 to 10.6) 0.94 4.4 (−5.9 to 14.7) 0.27 4.1 (−6.4 to 14.6) 0.31
52 weeks 10 (17) 9 (15) 16 (22) 0.24 (−10.2 to 10.7) 0.95 6.0 (−4.4 to 16.4) 0.14 5.8 (−4.7 to 16.2) 0.16
Overall Complaints on VAS (0: no complaints, 100: very large complaints)
6 weeks 51 (28) 50 (26) 32 (26) −1.5 (−9.2 to 6.2) 0.62 −6.9 (−14.7 to 0.9) 0.02 −5.4 (−13.3 to 2.4) 0.08
12 weeks 36 (27) 35 (28) 43 (30) 1.6 (−6.1 to 9.4) 0.59 −2.2 (−9.9 to 5.5) 0.47 −3.8 (−11.6 to 3.9) 0.21
26 weeks 18 (20) 19 (23) 36 (26) 1.9 (−5.9 to 9.7) 0.52 −0.5 (−8.3 to 7.3) 0.86 −2.5 (−10.4 to 5.5) 0.42
52 weeks 12 (19) 9 (13) 20 (24) 2.5 (−5.4 to 10.3) 0.42 −1.0 (−8.9 to 6.9) 0.74 −3.5 (−11.4 to 4.5) 0.26
Positive value favours first treatment in comparison
Pain‐free grip strength ratio (x 100)+
6 weeks 57 (32) 50 (29) 58 (35) 6.1 (−15.9 to 28.1) 0.47 1.8 (−20.6 to 24.22) 0.84 −4.3 (−26.9 to 18.2) 0.62
12 weeks 63 (36) 55 (25) 64 (43) 0.6 (−21.9 to 23.2) 0.94 −3.4 (−25.7 to 18.9) 0.70 −4.0 (−26.4 to 18.4) 0.65
26 weeks 74 (37) 76 (27) 82 (48) 10.0 (−12.9 to 32.8) 0.26 3.4 (−19.4 to 26.2) 0.70 −6.6 (−29.8 to 16.6) 0.47
52 weeks 91 (23) 90 (23) 100 (33) 11.8 (−11.7 to 35.4) 0.24 7.9 (−15.5 to 31.2) 0.39 −4.0 (−28.3 to 19.3) 0.66
Maximum grip strength ratio (x 100)+
6 weeks 74 (27) 80 (25) 87 (26) 1.7 (−14.6 to 18.0) 0.79 6.8 (−9.8 to 23.4) 0.29 5.1 (−11.6 to 21.8) 0.43
12 weeks 89 (28) 88 (23) 83 (29) −7.2 (−23.7 to 9.3) 0.26 −3.7 (−20.2 to 12.7) 0.57 3.6 (−13.0 to 20.1) 0.58
26 weeks 99 (19) 99 (20) 89 (27) −4.5 (−21.0 to 12.0) 0.48 −2.7 (−19.3 to 13.9) 0.67 1.8 (−15.1 to 18.6) 0.79
52 weeks 104 (15) 102 (17) 96 (19) −7.6 (−24.3 to 9.2) 0.25 −5.0 (−21.7 to 11.7) 0.44 2.6 (−14.3 to 19.4) 0.70
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Table 3 Secondary outcomes. Mean (sd) scores and percentage (99 % CI) for secondary outcome measures at each follow up. Between group differences in estimated mean
score using linear generalized estimating equations (GEE) regression model adjusted for significant covariates; between groups estimated odds ratio (OR) for no pain on two
isometric movements using logistic GEE regression model adjusted for significant covariates; 99 % confidence intervals (Continued)
Negative value favours first treatment in comparison
Pain Free Function Index (0–8, 0: full function, 8: no function)
6 weeks 4.82 (2.16) 4.40 (2.01) 2.78 (2.22) −0.13 (−1.20 to 0.94) 0.76 −0.52 (−1.60 to 0.57) 0.22 −0.39 (−1.49 to 0.71) 0.36
12 weeks 3.37 (2.36) 3.62 (2.43) 3.42 (2.63) 0.38 (−0.70 to 1.46) 0.36 −0.15 (−1.22 to 0.92) 0.72 −0.54 (−1.62 to 0.55) 0.20
26 weeks 2.00 (2.25) 1.83 (2.08) 2.97 (2.53) −0.04 (−1.12 to 1.05) 0.93 0.46 (−0.63 to 1.55) 0.27 0.50 (−0.61 to 1.60) 0.24
52 weeks 1.40 (1.90) 1.03 (1.67) 1.64 (2.04) −0.18 (−1.28 to 0.92) 0.67 0.01 (−1.08 to 1.11) 0.98 0.20 (−0.91 to 1.30) 0.65
Percentage (99 % CI) for each intervention Estimated Odds Ratio (99 % CI) between groups
OR > 1 favours first treatment in comparison
No pain on three point Likert scale on dorsiflexion of wrist++
6 weeks 8 (−1 to 18) 3 (−3 to 10) 36 (20 to 52) 0.38 (0.04 to 3.96) 0.29 3.47 (0.71 to 17.1) 0.04 9.2 (1.09 to 77.74)* <0.01
12 weeks 17 (4 to 29) 12 (1 to 23) 22 (8 to 36) 1.07 (0.06 to 18.18) 0.95 0.66 (0.07 to 5.82) 0.63 0.62 (0.04 to 9.01) 0.65
26 weeks 38 (22 to 54) 29 (14 to 45) 19 (6 to 32) 1.76 (0.13 to 24.65) 0.58 0.20 (0.02 to 1.63) 0.048 0.11 (0.01 to 1.45) 0.03
52 weeks 50 (33 to 67) 60 (4 to 77) 36 (20 to 52) 3.88 (0.29 to 53.02) 0.18 0.23 (0.03 to 1.71) 0.06 0.06 (0.01 to 0.69)* <0.01
No pain on three point Likert scale on isometric extension of third finger++
6 weeks 17 (4 to 29) 16 (3 to 28) 44 (27 to 61) 0.90 (0.22 to 3.70) 0.84 2.95 (0.81 to 10.72) 0.03 3.29 (0.88 to 12.27) 0.02
12 weeks 22 (8 to 35) 24 (10 to 39) 36 (20 to 52) 1.21 (0.18 to 8.03) 0.80 1.14 (0.19 to 6.97) 0.86 0.94 (0.15 to 5.87) 0.93
26 weeks 58 (42 to 75) 53 (37 to 70) 31 (15 to 46) 1.07 (0.17 to 6.61) 0.93 0.17 (0.03 to 0.96)* <0.01 0.16 (0.03 to 0.93)* <0.01
52 weeks 63 (47 to 79) 76 (61 to 90) 53 (36 to 69) 2.04 (0.30 to 13.96) 0.34 0.33 (0.06 to 1.98) 0.11 0.16 (0.03 to 1.06) 0.012
+: ratio affected/unaffected arm
++: no pain, some pain, strong pain
*: p < 0.01
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Table 4 Sick leave, additional treatments and adverse events. Use and length of paid sick leave, use of additional not per protocol
treatments and reported adverse events for each treatment group. Values are numbers (percentages) if not otherwise stated.
Chi-square test of independence and one-way analysis of variance for between groups association
Control Placebo injection with
physiotherapy
Corticosteroid
injection with
physiotherapy
P
(n = 60) (n = 58) Chi‐square test
Paid sick leave during 52 week follow‐up
Number (percentage) on leave 30 (52) 31 (56) 30 (55) 0.88
Duration of leave for those on sick‐leave:
Days on full leave mean (95 % CI) 43.6 (22.0 to 65.1) 73.2 (34.2 to 112.2) 47.1 (30.0 to 64.3) 0.25*
Days on partial leave mean (95 % CI) 60.0 (23.1 to 96.9) 22.0 (6.8 to 37.3) 29.2 (11.2 to 47.2) 0.07*
Additional treatments
Number of patients receiving additional
treatments
13 (23) 12 (22) 16 (30) 0.63
Type of treatment:
Pain killers 6 (11) 4 (7) 2 (4) 0.37
NSAIDs perorally 7 (13) 9 (16) 11 (20) 0.54
topical NSAIDs 3 (5) 1 (2) 2 (4) 0.62
other medication 3 (6) 0 (0) 3 (6) 0.22
physiotherapy 4 (7) 1 (2) 9 (17) 0.02+
other 6 (11) 4 (7) 4 (8) 0.76
Adverse Events
Patients reporting adverse events 9 (16) 5 (9) 6 (11) 0.51
Type of adverse events
increased pain 2 (4) 2 (4) 0 (0) 0.37
GI side effects** 8 (15) 3 (6) 6 (11) 0.30
skin atrophy 0 (0) 0 (0) 0 (0) ‐
*: one‐way ANOVA
**: heart burn/ dyspepsia, reflux symptoms, abdominal pain, gastritis, ulcer
+: p < 0.05
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additional physiotherapy in the follow-up period in the
CI with physiotherapy group compared to the placebo
injection with physiotherapy group. This might indicate
a negative effect of steroid injection.
CI with physiotherapy showed a large improvement in
success rate at six weeks, but at 12 and 26 weeks it was
lower than at six weeks. Patients in the control group
showed a statistically significant increase in odds ratio of
success over time and a gradual improvement across sec-
ondary outcomes. This large improvement would indicate
that the condition itself improves considerably without ac-
tive treatment, making it difficult to show significantly
better results for any treatment.
In addition to results that were statistically significant
with a chosen level of significance at 0.01, we also found
effects with a level between 0.01 and 0.05. These findings
may be considered clinically important even if they were
not statistically significant at our chosen level of p < 0.01.There was a non-significant tendency towards a positive
effect on treatment success for placebo injection with
physiotherapy compared to control at six weeks (p = 0.04),
but at 12 and 52 weeks, the tendency was negative (p =
0.04 and p = 0.03 respectively). At 12 weeks, we found a
tendency towards a negative effect for CI with physiother-
apy (NNT = 17, p = 0.02). There was a non-significant
tendency in favour of CI with physiotherapy at six weeks
and in favour of placebo injection with physiotherapy at
26 weeks. For some secondary outcomes, there were sig-
nificant differences at p < 0.05 between groups at a few
time-points (Table 3). Placebo injection with physiother-
apy was worse than control at 6 weeks for affected func-
tion on VAS, CI with physiotherapy was better than
control at 6 weeks for overall complaints on VAS, pain
free dorsiflexion of wrist and isometric extension of third
finger. At 26 weeks, CI with physiotherapy was worse than
control for pain-free wrist dorsiflexion. CI with physio-
therapy was worse than placebo injection with
Olaussen et al. BMC Musculoskeletal Disorders  (2015) 16:122 Page 12 of 13physiotherapy at 26 weeks for pain-free dorsiflexion of
wrist and extension of third finger, but better for isometric
extension of third finger at 6 weeks.
Strengths and weaknesses
We used a 52-week follow-up with several assessments
to register the development of outcomes over the nat-
ural course of the condition. The general practice setting
and the choice of ordinary, well known physiotherapeu-
tic treatment modalities would ensure good external val-
idity. Double blind injections and blinded assessors were
also strengths of the study. There were few dropouts
and the adherence to treatment protocol was good. There
were similar results across several outcomes. We chose to
use statistical models that would minimize Type-1 errors,
since this is a non-serious, self-limiting condition. We also
chose to take into account multiple testing and non-
independence of data across several follow-ups.
Strict inclusion criteria, especially the exclusion of
patients who had recently received other treatment, limit
the generalizability of our results. The patients were not
blinded to the physiotherapy treatment, and that may have
influenced outcome. We did not log the home exercises
and the use of only one physiotherapist limited the
generalizability. A strict physiotherapy protocol prohib-
ited an individual adjustment of treatment, and may
have influenced results. The long follow-up made it dif-
ficult to avoid use of not-per-protocol treatments. Pain-
killers and additional treatment may have influenced
results, but we found no differences in use between the
groups except for additional physiotherapy in the CI with
physiotherapy group. We did not look specifically at re-
currence rates, which might have given more information
for the group that received corticosteroid injection.
Differences to other studies
Our findings were in contrast to other recently published
studies [8, 11] and systematic reviews [9, 10, 15], which
have found a short-time effect of physiotherapy [11]. They
discourage the use of corticosteroid injection due to high
recurrence rates and a possible negative effect at 52 weeks
[8, 11]. There were important differences between these
studies and ours; we included only acute conditions and
had a general practice setting. In Coombes’ [11] and
Bisset’s [8] studies, the duration of symptoms were lon-
ger (16 and 22 weeks median respectively), indicating a
more chronic condition. On the other hand, a study in
general practice found that corticosteroid injection gave
a very good initial response and no worse results later
on, although 1/3 of patients had duration of symptoms
longer than 3 months [16]. Earlier studies investigating
the combination of physiotherapy and injection have found
no added benefit, Coombes for more chronic conditions
[11], others with shorter follow-up [12, 13]. Our resultsagree with this, and found no added effect of steroid injec-
tion. A third difference to earlier studies was the different
physiotherapeutic modalities used. Coombes and Bisset
used a multi-dimentional exercise program (‘Mobilization
with Movement’) that included isometric, concentric and
eccentric exercise. The eccentric exercise used in our study
was low load with 0.5–1 kg and 3 × 30 repetitions. Our
findings suggest that physiotherapy with eccentric exercise
might be less useful for acute conditions.
Tendinopathy is a continuum of changing conditions
[14], requiring different treatments at different stages.
Looking at the primary outcome of success, there seems
to be reasonable homogeneity between the control group
in our study and the placebo injection group in Coombes’
study [11], suggesting that the duration of symptoms and
study setting did not affect the outcome for these groups.
The largest difference in success between these two stud-
ies appears to be for the physiotherapy with placebo
groups, suggesting that the difference in the physical treat-
ments influenced the outcome more than setting and
duration of symptoms. Treatment with steroid injection
combined with physical treatment on acute lateral epicon-
dylitis seems to follow the well-known pattern of short-
term benefit and intermediate recurrence. Our long-term
results showed no worse effect than control or physical
treatment with placebo injection. Compared to other pub-
lished results [8, 11], the evidence for long-term ramifica-
tions of this treatment still seems uncertain.
Although much research has been done on cortico-
steroid injection alone, it would be interesting to study
the efficacy on acute conditions, using similar inclusion
criteria as in our study. The possible need for different
treatments at different stages in the course of the condi-
tions would be useful to investigate further, including
the possible difference in effect of physiotherapy on acute
and chronic conditions.
Conclusions and implications
Our results suggest that acute lateral epicondylitis is a
self-limiting condition where 3/4 of the patients recover
within 52 weeks without active treatment, but 1/4 had
long-lasting symptoms and the use of sick-leave and
additional treatments was high. Placebo injection with
physiotherapy consisting of deep transverse friction mas-
sage, Mills manipulation, stretching, and eccentric exer-
cises showed no clear beneficial effect on acute lateral
epicondylitis. For CI with physiotherapy, we found a
large positive effect on success of treatment at six weeks,
no difference at 12 weeks, worsening at 26 weeks but no
significant negative effect at 52 weeks compared to con-
trol. We found no significant differences between CI with
physiotherapy and placebo injection with physiotherapy,
suggesting no added effect of steroid injection. Secondary
outcome measures gave similar results.
Olaussen et al. BMC Musculoskeletal Disorders  (2015) 16:122 Page 13 of 13For patients needing a quick improvement, cortico-
steroid injections combined with the physiotherapeutic
treatment used in this study might be considered, but
they should be informed of a likely intermediate worsen-
ing of symptoms. This tendency makes the treatment
difficult to recommend in general, even if we found no
difference between groups at 52 weeks.
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